Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection

This article reviews the current evidence to classify donor-specific antibodies (DSAs) using Food and Drug Administration–National Institutes of Health Biomarkers, EndpointS, and other Tools (BEST) resource terms as diagnostic, prognostic, predictive, monitoring, and risk biomarkers for graft rejection. The emphasis is on DSA characteristics, including the DSA levels determined by mean fluorescence intensity and/or titers, the ability to...